§Why CasetextPricing

Linde, Inc.; Withdrawal of Approval of a New Drug Application and New Animal Drug Application for Helium, USP

89 Fed. Reg. 83883 (Oct. 18, 2024)

Linde, Inc.; Withdrawal of Approval of a New Drug Application and New Animal Drug Application for Helium, USP

Download PDF
Federal RegisterOct 18, 2024
89 Fed. Reg. 83883 (Oct. 18, 2024)
Document Headings

Document headings vary by document type but may contain the following:

  • the agency or agencies that issued and signed a document
  • the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  • the agency docket number / agency internal file number
  • the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

    • See the Document Drafting Handbook for more details.

    Department of Health and Human Services Food and Drug Administration
  • [Docket No. FDA-2024-N-4560]

    • AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) 205851 and the new animal drug application (NADA) 141-389 for the designated medical gas Helium, USP held by Linde, Inc., 175 East Park Dr., Tonawanda, NY 14150-7844. Linde, Inc. notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.

    DATES:

    Approval is withdrawn as of November 18, 2024.

    FOR FURTHER INFORMATION CONTACT:

    Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137, Kimberly.Lehrfeld@fda.hhs.gov; or Scott Fontana (HFV-180), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-0656, Scott.Fontana@fda.hhs.gov.

    SUPPLEMENTARY INFORMATION:

    On March 12, 2024, Linde, Inc. informed FDA that it is no longer marketing the designated medical gas Helium, USP and requested that FDA withdraw approval of NDA 205851 and NADA 141-389 under the processes in § 314.150(c) (21 CFR 314.150(c)) and § 514.115(d) (21 CFR 514.115(d)). Linde, Inc. has also, by its request, waived its opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) or an NADA or abbreviated new animal drug application under § 514.115(d) is without prejudice to refiling.

    Therefore, approval of NDA 205851 and NADA 141-389, and all amendments and supplements thereto, are hereby withdrawn as of November 18, 2024. Introduction or delivery for introduction into interstate commerce of Helium, USP, without an approved new drug application or an approved new animal drug application violates sections 505(a), 512(a), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a), 360b(a)(1), 331(a), and 331(d)). Any Helium, USP manufactured by Linde, Inc. pursuant to these applications that is in inventory on November 18, 2024 may continue to be dispensed until the inventories have been depleted or the drug product has reached its expiration date or otherwise become violative, whichever occurs first.

    Dated: October 9, 2024.

    Eric Flamm,

    Acting Associate Commissioner for Policy.

    [FR Doc. 2024-24106 Filed 10-17-24; 8:45 am]

    BILLING CODE 4164-01-P